Expertise in
19
conditions

Dr. Quynh-thu X. Le

Radiation Oncology
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Expertise in
19
conditions
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 

Overview

Quynh-thu Le is a Radiation Oncologist practicing medicine in Palo Alto, California.

Dr. Le is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Olfactory Neuroblastoma, and Teratocarcinosarcoma.

She is actively involved in clinical research, co-authoring 211 peer reviewed articles and participating in 9 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in CA

Hospital Affiliations

Stanford Health Care

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Valley Health
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Stanford Hospital and Clinics
965 High St, Palo Alto, CA 94301
Other Locations
Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I Study of d-Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I Study of d-Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Recruiting
Publish Date: July 28, 2026
Intervention Type: Other, Drug, Radiation
Study Drugs: D-Limonene Gelcaps, Cisplatin
Study Phase: Phase 1
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Enrollment Status: Recruiting
Publish Date: February 10, 2026
Intervention Type: Procedure
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
Enrollment Status: Recruiting
Publish Date: December 24, 2025
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer
A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer
Enrollment Status: Completed
Publish Date: January 30, 2024
Intervention Type: Drug, Other
Study Phase: Phase 3
View 6 Less Clinical Trials

211 Total Publications

Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Imaging-Detected Extranodal Extension in p16-Positive Oropharyngeal Cancer: Secondary Analysis of RTOG 1016.
Journal: JAMA otolaryngology-- head & neck surgery
Published: August 27, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Richard T. Hoppe
Radiation Oncology
Expertise in
15
conditions
Dr. Richard T. Hoppe
Radiation Oncology
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Hoppe is a Radiation Oncologist practicing medicine in Palo Alto, California. Dr. Hoppe is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Mycosis Fungoides, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), and Cutaneous T-Cell Lymphoma (CTCL).

Expertise in
9
conditions
Dr. Maximilian Diehn
Radiation Oncology
Expertise in
9
conditions
Dr. Maximilian Diehn
Radiation Oncology
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (1.1 miles away)
650-723-6171
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maximilian Diehn is a Radiation Oncologist practicing medicine in Palo Alto, California. Dr. Diehn is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
45
conditions
Dr. Scott G. Soltys
Radiation Oncology
Expertise in
45
conditions
Dr. Scott G. Soltys
Radiation Oncology
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (1.1 miles away)
650-724-1569
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Soltys is a Radiation Oncologist practicing medicine in Palo Alto, California. Dr. Soltys is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Metastatic Brain Tumor, Astrocytoma, Acoustic Neuroma, and Rhizotomy.

Frequently Asked Questions about Dr. Quynh-thu X. Le

How do I make an appointment with Dr. Quynh-thu X. Le?

You can book an appointment with Dr. Quynh-thu X. Le by calling their office at 650-723-6171. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Quynh-thu X. Le a top-rated expert for Nasopharyngeal Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Quynh-thu X. Le is classified as an Elite expert for Nasopharyngeal Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Quynh-thu X. Le specialize in?

While Dr. Quynh-thu X. Le is a Radiation Oncology, they have specific expertise in Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Olfactory Neuroblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Quynh-thu X. Le participate in research or clinical trials?

Yes. Dr. Quynh-thu X. Le has published 211 articles and abstracts on conditions like Nasopharyngeal Carcinoma. You can view a list of Dr. Quynh-thu X. Le's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Quynh-thu X. Le accept my insurance?

Dr. Quynh-thu X. Le accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 650-723-6171 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Le's expertise for a condition
ConditionClose
View All 16 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile